Skip to main content

Lindsay Dudfield, Executive Director and CEO of Jindalee Resources Limited, Executed MOU with POSCO Holdings For Joint Research At McDermitt Lithium Project

JINDALEE RESOURCES LIMITED  (ASX: JRL) (Jindalee, the Company) is an Australian exploration company with Tier 1 lithium deposits in its portfolio in the United States. The Company’s core goals are to discover world-class mineral deposits and generate shareholder wealth. The United States is one of the largest marketplaces for lithium demand, and Jindalee is a leading company committed to help meet future demand. The Company is focussing efforts into developing its McDermitt lithium deposit. Jindalee Resources was listed on the Australian Securities Exchange (ASX) on 11th July 2002 and raised AUD 2.70 million. Now, it is a pure-play United States lithium company. Jindalee’s Projects: In June 2018, the Company acquired McDermitt and Clayton North, two lithium sediment projects in the United States. Both projects are 100% owned by HiTech Minerals Inc., a wholly owned, US-based subsidiary of Jindalee. Several factors attracted the Company’s interest in these projects including: Potenti...
Post a Comment

Roquefort Therapeutics PLC (LSE: ROQ) And Randox Laboratories Strike Exclusive License Agreement For Medical Diagnostics

 Roquefort Therapeutics PLC (LSE: ROQ, OTCQB: ROQAF), a cancer-focused biotechnology company, has made a significant announcement recently. The Company has signed an EXCLUSIVE LICENSING AND ROYALTY AGREEMENT with Randox Laboratories Ltd., a global leader in medical diagnostics. The agreement (“Randox Licence Agreement”) pertains to Roquefort’s Midkine antibody portfolio and is limited to medical diagnostics.

As per the Randox Licence Agreement, Roquefort Therapeutics has granted Randox an exclusive worldwide (except Japan) license to use its Midkine antibodies in medical diagnostics. This license agreement is valid for ten years. The two companies will work together on a combined research programme to identify new cancer diagnostics that will be treatable with Roquefort’s Midkine therapeutics. This collaborative effort aims to leverage the strengths of both companies to develop innovative diagnostic solutions for cancer patients.

The agreement’s commercial terms remain undisclosed. Roquefort Therapeutics estimates a transaction value of over GBP 5 million from the deal over its ten-year term. With its partnership with Randox, Roquefort has validated its strategy of targeting Midkine. A heparin-binding protein found in cancer that forbids tumour cell death and promotes the metastatic spread and abides the treatment. By partnering with Randox, a leading company that produces life-saving diagnostics essential for clinical trials, ROQUEFORT THERAPEUTICS can continue focusing on developing first-in-class oncology drugs.

The Randox Licence Agreement complements the development of the first in class cancer medicine by identifying patients with cancer expressing Midkine.

These patients can benefit from Midkine therapeutics (antibodies or oligonucleotides) and be enrolled in pharmaceutical clinical trials, a core area for Roquefort Therapeutics.

The Company

ROQUEFORT THERAPEUTICS PLC (LSE: ROQ, OTCQB: ROQAF) is a biotech company listed focused on developing innovative drugs in the high-value and rapidly growing field of oncology. The Company is strategically positioning itself to partner with or sell to big pharma after successfully developing first-in-class oncology medicines. Roquefort Therapeutics PLC, listed in March 2021, has acquired Lyramid Pty Ltd., a leader in developing medicines for a new therapeutic target, Midkine. The Company has also recently acquired ONCOGENI LTD., founded by Professor Sir Martin Evans, Nobel Laureate.

Resource Link



Labels:

Comments

Post a Comment

Popular posts from this blog

Lindsay Dudfield, Executive Director and CEO of Jindalee Resources Limited, Executed MOU with POSCO Holdings For Joint Research At McDermitt Lithium Project

JINDALEE RESOURCES LIMITED  (ASX: JRL) (Jindalee, the Company) is an Australian exploration company with Tier 1 lithium deposits in its portfolio in the United States. The Company’s core goals are to discover world-class mineral deposits and generate shareholder wealth. The United States is one of the largest marketplaces for lithium demand, and Jindalee is a leading company committed to help meet future demand. The Company is focussing efforts into developing its McDermitt lithium deposit. Jindalee Resources was listed on the Australian Securities Exchange (ASX) on 11th July 2002 and raised AUD 2.70 million. Now, it is a pure-play United States lithium company. Jindalee’s Projects: In June 2018, the Company acquired McDermitt and Clayton North, two lithium sediment projects in the United States. Both projects are 100% owned by HiTech Minerals Inc., a wholly owned, US-based subsidiary of Jindalee. Several factors attracted the Company’s interest in these projects including: Potenti...
Post a Comment
Read more

Eclipse Metals Reports A Busy December 2022 Quarter

ECLIPSE METALS  (ASX: EPM and FSE: 9EU) (Eclipse or the Company) has released its quarterly report highlighting the project advancements and other activities during the December 2022 quarter. Here are the updates on the activities carried out by Eclipse. Multi-commodity Greenland Project Updates ECLIPSE METALS  has completed the maiden percussion drilling and trench sampling program at its SW Greenland multi-commodity project. Initial stages of exploration at Ivigtût mine precinct and Grønnedal carbonatite were completed in November 2022. Grønnedal Carbonatite Complex Thirty-one drill holes over a ~3.0km by ~1.5km area to vertical depths of between 3m and 22m were completed at the Grønnedal carbonatite complex, and trenches were excavated where drilling was impossible. The drill samples taken at Greenland were tested using a portable XRF (pXRF) analyser. Grønnedal carbonatite complex shows favourable praseodymium (Pr) and neodymium (Nd) ratios and may have global significance ...
Post a Comment
Read more

Platina Resources Limited signed a Joint Venture agreement with Chalice Mining for the Mt Narryer Gold Project

  PLATINA RESOURCES LIMITED  (ASX: PGM) (Platina or the Company) is a mineral resource exploration company based in Western Australia. The Company has inked a  JOINT VENTURE AGREEMENT WITH CHALICE MINING LIMITED , a mineral exploration and development company, to operate the Mt Narryer Gold Project. Terms of the Joint Venture Stage 1 earn-in : Initially, Chalice Mining will earn a  51% INTEREST  in the project by investing  AUD 600,000  within two years, which must include at least  AUD 150,000  in the first year Stage 2 earn-in : Chalice Mining can acquire an additional  24% INTEREST  in the project by investing an extra  AUD 1.8 MILLION  within the next two years Platina free cost carry : Once Chalice Mining has obtained a  75% INTEREST  in the Project, Platina Resources Limited will continue to be free cost carried until the Pre-Feasibility Study is completed Contribute & Dilute : After the Pre-Feasibility...
Post a Comment
Read more